New York State Teachers Retirement System Decreases Holdings in Roivant Sciences Ltd. $ROIV

New York State Teachers Retirement System decreased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 5.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 255,908 shares of the company’s stock after selling 14,313 shares during the quarter. New York State Teachers Retirement System’s holdings in Roivant Sciences were worth $7,089,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Fifth Third Wealth Advisors LLC lifted its stake in Roivant Sciences by 4.6% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock valued at $282,000 after buying an additional 445 shares in the last quarter. Oregon Public Employees Retirement Fund increased its stake in Roivant Sciences by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after buying an additional 500 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of Roivant Sciences by 1.3% during the fourth quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock valued at $868,000 after acquiring an additional 516 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the last quarter. Finally, Fifth Third Bancorp lifted its position in shares of Roivant Sciences by 15.8% in the fourth quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock valued at $94,000 after acquiring an additional 588 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on ROIV shares. Piper Sandler reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Leerink Partners set a $42.00 price objective on Roivant Sciences in a report on Thursday, May 21st. Weiss Ratings cut shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. TD Cowen upped their target price on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Finally, Guggenheim increased their target price on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday, May 26th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $33.59.

Roivant Sciences Stock Performance

Shares of ROIV stock traded up $0.16 during trading hours on Tuesday, reaching $35.55. The company had a trading volume of 576,101 shares, compared to its average volume of 6,084,984. The stock has a fifty day moving average of $30.38 and a 200-day moving average of $27.39. The company has a market capitalization of $25.57 billion, a price-to-earnings ratio of -59.20 and a beta of 1.11. Roivant Sciences Ltd. has a 12-month low of $10.70 and a 12-month high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The firm had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter last year, the business posted ($0.29) earnings per share. On average, analysts forecast that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Insiders Place Their Bets

In related news, Director Daniel Allen Gold sold 12,380 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.28, for a total value of $436,766.40. Following the completion of the sale, the director owned 13,689,166 shares of the company’s stock, valued at approximately $482,953,776.48. This represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CAO Jennifer Humes sold 13,538 shares of the firm’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total transaction of $384,073.06. Following the sale, the chief accounting officer owned 84,191 shares of the company’s stock, valued at approximately $2,388,498.67. The trade was a 13.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 2,359,225 shares of company stock worth $77,401,516. 10.80% of the stock is currently owned by company insiders.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.